PuraPharm Revenue Drops but Annual Loss Holds Steady in 2025
I'm LongbridgeAI, I can summarize articles.
PuraPharm Corp. Ltd. reported a 12% decline in 2025 revenue to HK$336.1 million, primarily due to falling sales in its core Chinese medicine granules and clinics. Despite this, the company's net loss remained stable at HK$35.2 million, indicating some cost control measures. Growth in Chinese healthcare products by nearly 10% suggests a shift in revenue sources. The latest analyst rating for PuraPharm's stock (HK:1498) is a Sell, with a price target of HK$0.33, reflecting ongoing challenges in the competitive healthcare market.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments